Cochrane · systematic review · CD011782
Pentasaccharides for the treatment of deep vein thrombosis
Brandao, GMS, Junqueira, DR, Rollo, HA, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
15
No studies
9
Included studies
NR
No studies 9 · 37.5%Ungraded 0 · 0%Very low 6 · 25%Low 5 · 20.8%Moderate 4 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis
Population: people > 18 years of age with a diagnosed deep vein thrombosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent venous thromboembolism Fondaparinux plus vitamin K antagonist vs standard therapy | RR 0.8 [0.43, 1.47] | 2 studies · 2658 participants | Moderate Downgraded: risk of bias, imprecision |
Major bleeding during the initial treatment Fondaparinux plus vitamin K antagonist vs standard therapy | RR 1.15 [0.39, 3.44] | 2 studies · 2645 participants | Moderate Downgraded: risk of bias |
Major bleeding Fondaparinux plus vitamin K antagonist vs standard therapy | RR 1.05 [0.64, 1.71] | 2 studies · 2645 participants | Moderate Downgraded: risk of bias |
All‐cause mortality Fondaparinux plus vitamin K antagonist vs standard therapy | RR 0.93 [0.45, 1.91] | 2 studies · 2645 participants | Moderate Downgraded: risk of bias, imprecision |
Heparin‐induced thrombocytopenia ‐ not measured Fondaparinux plus vitamin K antagonist vs standard therapy | no estimate extracted | NR | No studies |
All harmful effects Fondaparinux plus vitamin K antagonist vs standard therapy | RR 0.84 [0.76, 0.93] | 1 study · 2192 participants | Very low Downgraded: risk of bias, imprecision |
Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis
Population: people > 18 years of age with a diagnosed deep vein thrombosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent venous thromboembolism Idrabiotaparinux vs idraparinux | RR 0.72 [0.31, 1.69] | 1 study · 757 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding during the initial treatment ‐ not reported Idrabiotaparinux vs idraparinux | no estimate extracted | NR | No studies |
Major bleeding Idrabiotaparinux vs idraparinux | RR 0.21 [0.06, 0.71] | 1 study · 755 participants | Low Downgraded: risk of bias, imprecision |
All‐cause mortality Idrabiotaparinux vs idraparinux | RR 0.48 [0.18, 1.27] | 1 study · 757 participants | Low Downgraded: risk of bias, imprecision |
Heparin‐induced thrombocytopenia ‐ not reported Idrabiotaparinux vs idraparinux | no estimate extracted | NR | No studies |
All harmful effects Idrabiotaparinux vs idraparinux | RR 0.92 [0.83, 1.02] | 1 study · 757 participants | Very low Downgraded: risk of bias, imprecision |
Low molecular weight heparin and idraparinux compared to standard therapy for the treatment of deep vein thrombosis
Population: people > 18 years of age with a diagnosed deep vein thrombosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent venous thromboembolism Low molecular weight heparin and idraparinux vs standard therapy | RR 1.51 [0.26, 8.9] | 1 study · 263 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding during the initial treatment Low molecular weight heparin and idraparinux vs standard therapy | no estimate extracted | NR | No studies |
Major bleeding Low molecular weight heparin and idraparinux vs standard therapy | RR 3.76 [0.5, 28.19] | 1 study · 659 participants | Very low Downgraded: risk of bias, imprecision |
All‐cause mortality Low molecular weight heparin and idraparinux vs standard therapy | no estimate extracted | NR | No studies |
Heparin‐induced thrombocytopenia Low molecular weight heparin and idraparinux vs standard therapy | no estimate extracted | NR | No studies |
All harmful effects Low molecular weight heparin and idraparinux vs standard therapy | no estimate extracted | NR | No studies |
Idraparinux compared to standard therapy for the treatment of deep vein thrombosis
Population: people > 18 years of age with a diagnosed deep vein thrombosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent venous thromboembolism Idraparinux vs standard therapy | RR 0.98 [0.64, 1.48] | 1 study · 2904 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding during the initial treatment Idraparinux vs standard therapy | no estimate extracted | NR | No studies |
Major bleeding Idraparinux vs standard therapy | RR 0.71 [0.34, 1.47] | 1 study · 2904 participants | Very low Downgraded: risk of bias, imprecision |
All‐cause mortality Idraparinux vs standard therapy | RR 1.14 [0.69, 1.86] | 1 study · 2904 participants | Low Downgraded: risk of bias, imprecision |
Heparin‐induced thrombocytopenia Idraparinux vs standard therapy | no estimate extracted | NR | No studies |
All harmful effects Idraparinux vs standard therapy | RR 1.03 [1, 1.06] | 1 study · 2904 participants | Very low Downgraded: risk of bias, imprecision |